Last reviewed · How we verify
Copaxone
At a glance
| Generic name | Copaxone |
|---|---|
| Also known as | glatiramer acetate, Copaxone 20 mg injected SQ every day (glatiramer acetate), Cop 1, Glatiramer Acetate, Glatiramer acetate |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Multiple sclerosis
Common side effects
- Injection Site Erythema
- Injection Site Pain
- Injection Site Pruritus
- Injection Site Mass
- Asthenia
- Pain
- Injection Site Edema
- Rash
- Vasodilatation
- Chest Pain
- Nausea
- Dyspnea
Serious adverse events
- Thrombocytopenia
- Injection site reactions
- Dyspnea
- Urticaria
- Hypersensitivity
Key clinical trials
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (PHASE3)
- Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis (NA)
- Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation (NA)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Copaxone CI brief — competitive landscape report
- Copaxone updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI